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Abstract: Tuberculin skin testing (TST) and Interferon-gamma (IFN) release assays (IGRAs) are presently the only 
available assays for the detection of Mycobacterium tuberculosis infected individuals. IGRAs might progressively replace 
TST, as numerous published reports establish their higher specificity and similar sensitivity when tested in BCG vacci-
nated, immunocompetent individuals or in populations who may have been in contact with atypical mycobacteria. How-
ever, few published reports have commented on their role in TB diagnosis in immunocompromised individuals (HIV, 
immunosuppressive therapy, cancer…). It is the purpose of this report to review IGRAs published studies in HIV indi-
viduals in endemic and non endemic area for tuberculosis (TB). IGRAs were tested in the presence or absence of active 
TB but correlated to duration of exposure. In newly diagnosed active TB, IGRAs demonstrated a similar sensitivity to 
TST. In TB non infected individuals, TST and IGRAs also gave similar values when categorization of individuals was 
correlated to the risk of infection. A higher number of positive IGRAs was observed in individuals from TB endemic ar-
eas, in similar proportions to immunocompetent individuals. Comparison between the two IGRAs: QuantiFERON-TB 
Gold
® (QF-TB, Cellestis, Australia) and T-SPOT-TB
® (Oxford Immunotec, UK), and against TST, in the same HIV 
population demonstrates a higher sensitivity of T-SPOT-TB and TST than QF-TB. Indeterminate results, which corre-
spond to the absence of a positive T-cell IFN response towards phytohemaglutinin (PHA), is a key point when compar-
ing both IGRAs. This PHA control is indicative of the level of immunosuppression observed in the tested individual. QF-
TB seems to present, in HIV populations, more indeterminate results than T-SPOT-TB. The calibration and/or concentra-
tion of PBMC on nitrocellulose membrane for the T-SPOT-TB, as compared to a whole blood assay, might explain this 
difference, with less indeterminate results with the T-SPOT-TB assay. Neither assay is able to differentiate active TB 
from latent TB infection (LTBI). Several laboratories have tried new antigenic epitopes to solve this issue. It is of impor-
tance that these studies need to be repeated on a larger scale by others to validate their results. Two blood assays might 
add information characterising the evolution from LTBI to active TB: either by losing protective immunity, as demon-
strated by the whole blood killing assay, or by evaluating the kinetics of the antibodies synthesized against M. tuberculo-
sis specific antigens. In conclusion, longitudinal studies are still needed to validate IGRAs and other assays and to define 
their respective predictive values. 
Keywords: Tuberculin skin test, Interferon-gamma release assays, HIV-infected, latent tuberculosis infection, active tuberculo-
sis, whole-blood killing assay, ELISA, antibody, PGL-Tb1. 
INTRODUCTION 
  In most individuals infection with Mycobacterium tuber-
culosis is contained by the host’s immune defences and the 
infection remains latent [1,2]. The World Health Organisa-
tion (WHO) has estimated that approximately a third of the 
world’s population is infected with M. tuberculosis, the vast 
majority with Latent Tuberculosis Infection (LTBI) [3]. The 
M. tuberculosis bacilli that persist in symptom-free immuno-
competent individuals with LTBI, can reactivate however, 
and cause active TB disease in about 10% of those infected 
over a lifetime [4]. Currently, it is difficult to predict exactly 
when and who among the latently infected individuals will 
develop the disease. Targeted testing and treatment for LTBI 
in high risk populations is a key component of TB control in 
many low-incidence, high income countries as a conse-
quence of this risk of progression from LTBI to active TB 
disease [5]. 
 
 
*Address correspondence to this author at the Service de Microbiologie, 
Hôpital Saint Louis, Paris, France;  
E-mail: philippe-henri.lagrange@sls.aphp.fr 
  The rational of such preventive treatment is also linked to 
TB transmission in the community occurring mostly before a 
diagnosis of TB is made in the index case, even when an 
optimal TB control program is in place: new and undiag-
nosed cases are the driving force behind the current TB epi-
demic [6]. It has been calculated that if each new TB case 
infected up to 10 susceptible contacts before diagnosis, up to 
40 million new infections might occur worldwide every year, 
adding to the pool of existing LTBI [7]. Implementation of 
an effective screening program in high risk populations that 
would identify individuals with LTBI and treat them to pre-
vent disease would be of enormous operational value. 
  The determinants for increased risk of progression from 
LTBI to active TB disease are a recent infection with M. 
tuberculosis and several host-related factors, all of which 
seems to be associated with an impaired cell-mediated im-
mune response [8]. Among this high risk populations, indi-
viduals infected with the Human Immunodeficiency Virus 
(HIV) are the most prone to reactivate the persistent M. tu-
berculosis bacilli. Likewise, after a primary infection, the 
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viduals is increased many fold, even when antiretroviral 
chemotherapy is given [9-11], and the incidence of TB is 
increasing in regions where HIV is prevalent [3]. As de-
scribed in the Global Plan to Stop TB 2006-2015, manage-
ment of LTBI in high HIV prevalence settings will be of 
paramount importance, together with DOTS expansion and 
provision of a tuberculosis/HIV package of prevention and 
care, to control and eventually to eliminate tuberculosis [12]. 
  For several decades, identification of individuals with 
LTBI has been conventionally performed using the Tubercu-
lin Skin Test (TST) [13]. Several studies have demonstrated 
its prognostic value with correct correlation between a posi-
tive test and potential occurrence of active TB
 [14-16]. Sev-
eral prospective studies using TST have established the 
benefit of prophylactic therapy in individuals with LTBI, 
either in a setting of HIV co-infection or not
 [17-19]. How-
ever, accumulated experience has led to a full understanding 
of the limitations and drawbacks of TST. The limitations of 
TST in this setting is the need for two visits [20], the subjec-
tive nature of the test placement and its interpretation, and 
false-positive reactions due to Bacille Calmette-Guérin 
(BCG) vaccination and exposure to non tuberculous myco-
bacteria (NTM) [13]. In addition, HIV-infected patients have 
a higher rate of specific and non-specific unresponsiveness 
(anergy), particularly with advanced immunosuppression 
[21-24]. Thus, new tests for diagnosing LTBI are warranted, 
and ideally such tests should have several characteristics: a 
high sensitivity in all populations at risk, and a high specific-
ity, regardless of BCG vaccination or infection with envi-
ronmental NTM. It should also be reliable, stable over time, 
and with objective criteria for a positive result. Because, 
most of the LTBI occurred in high incidence, resource-
limited countries; this test should also be inexpensive and 
easy to perform. 
 Presently,  two  in vitro assays called IFN-released assays 
[IGRAs; QuantiFERON-TB Gold
®
  in Tube (QF-TB-IT, 
Cellestis, Australia) and T-SPOT-TB
®
 (Oxford Immunotec, 
UK)] have been developed and are commercially available. 
They measure the T-cell IFN production after 16 to 24h of 
contact with M. tuberculosis specific antigens coded by the 
region of deletion 1 or RD1 (ESAT-6 + CFP-10 for T-SPOT-
TB, and ESAT-6 + CFP-10 + Tb7.7 for QF-TB-IT). Both 
assays have a negative and a positive control, the latter being 
represented by the T-cell response towards the phytohema-
glutinin PHA. Both assays, in addition to TST, are the only 
available assays for the diagnosis of M. tuberculosis infected 
individuals. 
  Comparison between IGRAs and TST has been per-
formed, either in well defined active TB patients to establish 
their respective sensitivity or in well defined controls with-
out any contact risk with a TB index case to establish their 
respective specificity. As is clearly evident, we do not bene-
fit from a gold standard to define such a control population 
to compare with active TB patients where a positive culture 
represents the gold standard. 
  To deal with LTBI diagnosis, investigators have used two 
approaches. In the first one, investigators compared directly 
the results of the TST with those of the IGRAs and calcu-
lated a degree of agreement (using the Cohen’s kappa coeffi-
cient). With the second approach, investigators designed 
studies to establish the extent of which the test performance 
fits with a defined attribute (e.g., the likelihood of infection 
based on clinical or epidemiological characteristics). This 
second approach is consistent with a causal relationship and 
thereby strengthens the assessment of the validity (e.g., the 
gradient of exposure as an indicator of the likelihood of re-
cent LTBI). 
  Several recent reviews have shown considerable promise 
for IGRA as a new diagnostic tool for LTBI in immunocom-
petent TB infected individuals
 [25-30]. IGRAs when com-
pared to TST do not cross-react with immune responses elic-
ited by BCG vaccination and NTM exposure. In addition, 
IGRA results have shown a higher sensitivity than TST in 
low endemic TB countries. Recent meta-analysis has further 
emphasized these results with suboptimal sensitivities (TST: 
71%; QF-TB: 76%; ELISPOT: 88%) and high pooled 
specificities (TST: 66%; QF-TB: 97%, ELISPOT: 92%) 
[31]. Both assays were more specific than TST in samples 
from individuals vaccinated with BCG. Discordant TST and 
IGRAs reactions were frequent and largely unexplained 
(definitions used for the positive test results, the study popu-
lation, the sample sizes, and the study design) [32-34]. 
  Compared to the extensive numbers of studies performed 
in immunocompetent individuals infected with M. tuberculo-
sis, there are only limited data describing IGRA performance 
in HIV-infected individuals, who’s immunological impair-
ment may affect the performance of these lymphocyte-based 
assays. It is the purpose of this review to analyze the pub-
lished studies relative to the usefulness and limitations of the 
IGRA in HIV infected individuals in comparison with the 
TST. 
REVIEW 
1. New T-Lymphocyte-Based Tests for LTBI 
1.1. The IGRA Performances in HIV Infected Individuals 
  The first study was done in Zambian HIV-positive [35]. 
An “in-house” PPD and RD1 antigens ELISPOT was com-
pared to TST in 39 HIV-TB coinfected patients (with ad-
vanced immunosuppression), 11 HIV-negative patients with 
active TB disease and in the 54 HIV-negative asymptomatic 
Zambian healthy adults. PPD and RD1 ELISPOT gave iden-
tical results in HIV uninfected patients (100%, Table 1); but 
gave fewer positive responses in HIV- positive co-infected 
TB patients. RD1 ELISPOT positive responses were, how-
ever, more frequent than PPD ELISPOT positive responses 
in the same HIV-positive co-infected TB patients (Table 1). 
Finally, TST and PPD ELISPOT were more often positive 
than RD1 ELISPOT in healthy control individuals (Table 1) 
[35]. Of note, three RD1 ELISPOT positive, HIV-positive 
but TB negative were PPD ELISPOT and TST negative
 [35]. 
IGRAs might perform well in HIV-infected patients even 
better as compared to TST. However, this “in-house” assay 
was performed in a relatively low number of patients and the 
CD4+ cell counts per patient were not reported. 
  Following this study, several recent reports evaluated 
IGRAs performance in HIV- infected patients with active TB 
(Table 2) [36-38]. The prevalence of the TST positive re-
sponses was always lower than the proportion of IGRA posi-
tive responses in HIV-infected patients with active TB. In 
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QF-TB assays were identical showing 85 to 90 % of positive 
responses. 
  In HIV-infected patients without any TB disease, IGRAs 
results were more variable and might reflect the different TB 
epidemiological situations in the countries where the studies 
were performed. Higher positive responses were observed in 
patients from South Africa compared to European patients. 
  Twice the number of published studies described specific 
results that were obtained in individuals with LTBI compar-
ing the respective prevalence of positive results in TST with 
those with IGRAs, half being evaluated in low endemic re-
gions, the other half in high endemic regions (Table 3) [39-
44]. 
  In three large cohorts performed in low endemic coun-
tries, data showed that only a limited number of HIV-
infected individuals had positive IGRA (4.1 to 8.5%), and 
almost 80% of these individuals with IGRA positive results 
had risk factors for LTBI (history of exposure, long term 
residency in a high endemic country) [39-41]. When tested 
simultaneously, TST and QF-TB-IT gave comparable posi-
tive results. 
  In the three studies performed in high endemic countries, 
a higher frequency of IGRA and TST positive results was 
observed related to higher transmission rate of M. tuberculo-
sis in this population [42-44]. TST positive results ranged 
from 83% (in HIV-negative LTBI individuals) to 21.4% 
(HIV-positive LTBI individuals). In the study performed by 
Rangaka and coworkers, significantly fewer (p<0.01) TST 
positive results were obtained in the HIV-infected group as 
compared to the HIV-uninfected group regardless of TST 
cutoff [42]. A similar decrease in positive TST results in 
HIV-infected individuals with LTBI was shown recently in 
India [45]. In comparison, IGRA results gave more homoge-
neous results. When the 2 IGRAs were tested simultane-
ously, higher numbers of individuals scored with a T-SPOT 
positive response as compared to QF-TB-G, in HIV-infected 
(52%  vs 43%) and HIV-non infected individuals (59% vs 
46%, respectively). However, such differences were not sta-
tistically significant (p=0.07) [42]. 
1.2. Stratification of Results in HIV-Infected Individuals by 
CD4+ Cell Count 
  Both IGRAs depend predominantly on the CD4+-T-cells 
recognition of M. tuberculosis antigens. Test performance in 
the HIV-infected group will be affected by the absolute 
CD4+-T-cells count. Similarly, the positive control (using 
non-specific stimulation with PHA) depends on absolute 
CD4+ cell count. The PHA control is indicative of the level 
of immunosuppression observed in the tested individual, and 
interpretation of IGRAs depends on its positive result. A 
negative PHA result will confer an indeterminate response of 
the IGRAs. These two aspects have been explored by strati-
fying the CD4+ T-cells count with IGRAs results
 [39-44]. 
Table 1.  Frequency of Positive Results in Zambian TB Patients and Healthy Individuals According to their HIV Status Tested 
with TST or with ELISPOT. Data from Chapman et al. [35] 
 
ELISPOT 
Patients Tested  HIV Status  TST (5 TU) 
PPD ESAT6/CFP10 
TB disease 
negative 
positive 
NT* 
NT* 
11/11 (100%) 
28/39 (72%) 
11/11 (100%) 
35/39 (90%) 
Healthy Zambian 
negative 
positive 
28/35 (80%) 
5/14 (36%) 
45/54 (83%) 
6 /21 (29%) 
37/54 (69%) 
9/21 (43%) 
Healthy UK**  Negative  NT*  33/40 (83%)  0/40 (0%) 
*NT: non tested 
**30/48 (80%) have been BCG vaccinated. 
Table 2.  Proportion (in Percentage) of IGRA Indeterminate and Positive Results in Groups of HIV-Infected Patients with Active 
Tuberculosis and in HIV-Positive Patients without Tuberculosis Tested with TST, T-SPOT-TB and QuantiFERON –TB 
 
Tests 
IGRA  Reference  Diagnosis  Number Subjects  Mean CD4+/μL 
TST SPOT  QF-TB Indeterminate 
Active TB  45  152  47.0  84.6  84.6  20.0 
Vincenti (Italy) [36] 
Non TB  66  236  39.9  35.7  25.0  18.2 
Active TB  41  167  67.0  90.0  90.0  12.2 
Non TB  41  464  51.0  75.0  79.0  7;3  Rangaka (South Africa) [37] 
HIV (-) controls  41  NA*  69.0  83.0  83.0  0.0 
Active TB  154  209  NT**  90.3 NT**  4.5 
Clark (UK) [38] 
LTBI 47  294  NT**  20.0 NT**  4.5 
* NA: non applicable. 
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  Variable percentages of indeterminate results were no-
ticed according to the CD4+ cell count using QF-TB-IT [39-
41]; with a higher proportion of indeterminate results in pa-
tients with low CD4+ cell counts. In individuals with CD4+ 
cell count lower than 100 cells/L proportion of indetermi-
nate results were 24%, 16%, and 37% in these three studies, 
respectively (Fig. 1) [39-41]. In studies using the T-SPOT-
TB, fewer indeterminate results were observed. Numbers of 
interpretable T-SPOT-TB assays seemed less influenced by 
the CD4+ cell counts (Fig. 2), as already described by Dedha 
et al. [46]. 
 
Fig. (1). Percentage of indeterminate responses (white column) 
positive responders to QuantiFERON-TB-IT (black column) and to 
TST (grey column) stratified by CD4+ cell count. Data from Jones 
et al. [41]. 
  For this reason, enhanced performances in a higher pro-
portion of tuberculosis identified infected subjects in the 
lower CD4+ cell count group was observed for T-SPOT-TB 
as compared to QF-TB-G or QF-TB-IT (Figs. 1,2). 
  In conclusion, commercially available IGRAs have 
evolved rapidly over the past decade. The latest generation 
of QF-TB-IT uses more specific antigens and is simpler to 
perform. In our review, the different studies performed in 
HIV-positive patients showed that, in contrast to the TST, 
HIV infection does not appear to substantially undermine the 
IGRA responses in patients with active TB [36-38] or LTBI 
[39-44]. However, the proportion of both QF-TB and T-
SPOT-TB positive results decreases with advanced immune 
suppression; such a decline seems to be more important for 
QF-TB than for the ELISPOT assay. Moreover, the propor-
tion of indeterminate results increases with advanced im-
mune suppression and again is more likely with QF-TB-IT 
than with T-SPOT-TB. Because lymphopenia is often found 
in advanced HIV-associated immunodeficiency
 [47], a nor-
malized input of PBMC used in ELISPOT assays may partly 
explain why this assay appears to retain its efficiency among 
patients with low CD4+ cell counts. The other commercially 
available IGRAs (QF-TB-G, or QF-TB-IT), although pro-
ducing easier logistic calculation in which the cell input is 
not normalized, could suffer from a high rate of indetermi-
nate results among those HIV-infected patients with ad-
vanced immunodeficiency [39-41]. 
 
Fig. (2). Percentage of indeterminate responses (white column) 
positive responders to ESAT-6/CFP10 ELISPOT (black column) 
and to TST (grey column) stratified by CD4+ cell count. Data from 
Karam et al. [43]. 
1.3. Need for Further Studies 
  The two major limitations of these new ex vivo IGRAs 
for diagnosing LTBI are firstly, that they are not able to dif-
ferentiate LTBI from active TB and secondly, that they are 
not predictive of the development of active TB. 
Table 3.  Proportion (in Percentage) of IGRA Indeterminate and Positive Results in Cohorts of HIV-Infected Patients with Latent 
Tuberculosis Infection and in HIV-Negative Control Patients Tested with TST, T-SPOT-TB and/or QuantiFERON –TB 
in Low or High Endemic Tuberculosis Areas 
 
IGRA Results 
Reference Subjects  Number  Mean  CD4+/μL  TST (%) 
T-SPOT QF-TB  Indeterminate 
Brock (Denmark) [39]  cohort  590  523  NT  NT(a)  4.1  3.4* 
Luetkemeyer (USA) [40]  cohort  294  132  9.3  NT(a)  8.5*  5.1* 
Jones (USA) [41]  cohort  201  453  6.8  NT  5.8  4.9* 
HIV(+) 74  392  52*  52.0  43.0  7.0* 
Rangaka (South Africa) [42] 
HIV(-) 86  NA(b)  83  59.0  46.0  2.0 
Karam (Senegal) [43]  cohort  285  180  21.4*  50.6*  NT  13.3* 
Lawn (South Africa) [44]  cohort  40  114  43  62.0  NT  10.0 
(a); NT: non tested; (b); NA: non applicable. 
* CD4+ cell counts dependent frequency. 
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  Recently Rangaka and coworkers [37, 42] reported an 
interesting approach to better identify patients with active 
TB among HIV-infected patients. This method directly cor-
relates the ELISPOT results of RD1 proteins stimulation 
with the CD4+ T-cell count of each single patient. Using the 
ratio of combined T-SPOT-TB results to CD4+ cell count 
the authors showed that a ratio >1 was significantly more 
frequently observed in patients with active TB compared to 
latent TB. However, recent published data seemed to contra-
dict such a prediction showing that the indicated ratio was 
not able to distinguish LTBI from active TB [48]. 
  To be able to identify those individuals who do not pro-
gress to active disease, large scale-scale cohort studies with 
long-term follow-up of untreated populations exhibiting 
positive results at baseline are required. Ongoing studies are 
in progress in endemic area trying to evaluate the risk for 
active disease associated with a particular test measure 
(quantitative versus dichtotomic results), as shown in unin-
fected HIV individuals [49, 50]. 
1.4. New Directions for New Tests 
  Several research groups have evaluated other RD1 or RD 
coded protein or peptides than those developed by the com-
mercial companies. Different selected RD1 peptides have 
been developed and tested in Italy by Goletti and coworkers. 
The authors showed that an assay based on RD1 selected 
peptides has a higher diagnostic accuracy for active TB in a 
clinical setting compared with commercially available assays 
based on RD1 overlapping peptides in HIV-infected or unin-
fected patients [36, 51, 52]. 
  Other developments concern antigens present at the sur-
face of M. tuberculosis. One group has assessed the diagnos-
tic potential of a novel 28-kD mycobacterial protein, the 
heparin-binding hemaglutinin (HBHA), previously shown to 
stimulate high levels of IFN- secretion by the peripheral 
blood lymphocytes of LTBI subjects in comparison with QF-
TB-IT [53]. The conclusion of the authors was that the 
commercially available IGRA may underestimate the inci-
dence of LTBI, whereas the use of HBHA may combine the 
operational advantages of IGRAs with higher sensitivity and 
specificity for latent TB infection [53]. 
  Other groups have tried to measure the different cytoki-
nes (IFN-, IL-2, IL-10) released after stimulation with se-
lected antigens to differentiate a population at high risk of 
active TB, showing a higher ratio of IFN-/IL-10 in pro-
tected individuals [54]. 
2. New Ex Vivo Cell-Mediated Killing Assay 
  Other researchers are looking for biomarkers for innate 
immunity or acquired immune protection. It has been re-
ported that in vitro cell-mediated killing assays may provide 
a promising measure of the functional capacity of cells to kill 
mycobacteria
 [55]. 
  Whole blood killing assays (WBKA) have the advantage 
of including all cells with potential anti-mycobacterial activ-
ity compared to infection of isolated differentiated mono-
cytes and are more easily adapted for use in large scale stud-
ies. Inhibition of in vitro growth of the bacilli has been 
measured using different techniques: conventional liquid 
medium culture (BACTEC system, BD), or luminescent 
readout of reporter-gene-tagged BCG (BCG lux) expressing 
a recombinant luciferase enzyme. 
  Using the second methodology, a study reported an asso-
ciation between low CD4+ cell counts, low IFN- production 
and impaired ability to regulate growth of M. bovis BCG in 
blood from HIV-infected children in South Africa
  [56]. A 
more recent study from the same authors reported that this 
WBKA was able to monitor in vitro the anti-mycobacterial 
immune response of HIV-infected children during anti-
retroviral therapy
 [57]. The authors confirmed their earlier 
results showing that before HAART the blood from HIV-
infected children demonstrated a low ability to restrict the 
growth of BCG in the functional WBKA; in contrast the in-
troduction of HAART was followed by rapid and sustained 
reconstitution of specific antimycobacterial immune re-
sponse, measured as a decrease in growth of the bacilli. This 
in vitro model mirrors the in vivo observation of decrease 
susceptibility to TB in HIV-infected adults receiving 
HAART [58]. 
3. Preclinical Detection of Antibody 
  Tests for serodiagnosis of TB, either based on ELISA or 
immunochromatographic strip technology, have been devel-
oped and have been evaluated in immunocompetent patients 
with active TB. The tests, with the best performance charac-
teristics, have an observed sensitivity and specificity around 
60% and 90%, respectively
 [59], demonstrating that the ex-
isting serological tests cannot be used as stand-alone diag-
nostic test for TB. Moreover, it has been generally observed 
that HIV-infected individuals with TB have suppressed anti-
body levels
 [60]. In this last study, the authors showed that 
while all HIV-negative and PPD-positive patients had IgG 
antibodies recognizing the 38-, 28-, and 19-kDa M. tubercu-
losis antigens, only 26% of those HIV-positive and PPD-
positive (all with < 400 CD4+ cells/mm3) and none of the 
HIV-positive tuberculosis patients recognized these antigens. 
In an effort to increase the performance of potential serologi-
cal tests, it was relevant to explore whether novel proteins or 
non-protein antigens specific for M. tuberculosis were able 
to significantly increase sensitivity and specificity. Several 
proteins, TB16.3, TB9.7, U1, and Mtb81, have been de-
scribed as serodiagnostic antigens that perform as well as or 
even better in the HIV-infected group, as recently reviewed 
[61, 62]. 
  Different authors have also shown that antibodies detect-
ing glycolipid antigens (PGL-TB1, DAT), specific for M. 
tuberculosis, were present in HIV-TB co-infected patients 
with levels higher than those in HIV uninfected TB patients 
[63, 64]. Moreover, antibodies to two recombinant proteins 
(MPT51 and Mtb81), and PGLTb1 or DAT antigens have 
been shown to be present in serum samples obtained during 
sub-clinical TB in a high proportion of HIV-infected patients 
tested [63-65]. 
 Although,  ex vivo tests based on cellular immune re-
sponse (IGRAs) performed in HIV-infected individuals with 
advanced immunodeficiency (with CD4+ lower than 100 
cells / μL) have been shown to be associated with a high 
proportion of indeterminate results, the anti-PGL-Tb1 anti-
bodies levels have been demonstrated to be independent of 
the CD4+ cell counts [63]. Thus, insight into the serological 
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sub-clinical TB could provide additional markers that iden-
tify incipient infection with M. tuberculosis before progres-
sion to clinical disease occurs [63, 65]. 
4. Potential New Algorithm for Detecting and Treating 
HIV-Infected Persons at High Risk for Progression to 
Active TB 
  Using the various blood assays described above, and de-
pending on their validation in large scale longitudinal stud-
ies, a new algorithm might be considered (Fig. 3). 
  In low or high endemic TB areas, all HIV-infected indi-
viduals should be first tested with IGRAs (QF-TB-IT or T-
SPOT-TB) and then stratified according to their level of im-
muno- suppression. Those individuals with a CD4+ cell 
count higher than 50-100 cells/L will potentially have ei-
ther a positive or a negative IGRA response. Individuals with 
a negative response (meaning absence of recent TB trans-
mission), should have serial IGRA testing at regular interval 
(every 6 months). Individuals with a positive response 
(meaning the presence of recent TB transmission) should be 
tested with the WBKA to evaluate their potential antimyco-
bacterial immune protection. If a positive response (surro-
gate maker showing the capacity to restrict in vitro growth of 
M. tuberculosis or BCG) is detected, these individuals could 
be considered as immune and should not receive any anti 
tuberculous prophylaxis. If a negative WBKA response is 
detected, such recently infected individuals without any spe-
cific immunity should be considered for anti TB chemopro-
phylaxis. A certain proportion of Individuals, with < 50-100 
CD4+ cell count /L may produce an IGRA positive re-
sponse and the same protocol as above should be followed 
for IGRA positive response. For those individuals with inde-
terminate or negative results with IGRA, the only suitable 
test that might demonstrate infection with TB is the meas-
urement of circulating IgG anti-PGL-Tb1 antibody. Indi-
viduals with ELISA positive results should be considered at 
high risk and should received anti-TB chemoprophylaxis 
after eliminating active TB disease. A systematic approach 
for blood culture testing to detect circulating mycobacteria 
should also be considered. For those without circulating anti-
PGL-Tb1 antibody should be considered for empirical 
HAART [66]. 
CONCLUSIONS 
  There is a definite need to diagnose and treat LTBI in all 
HIV-infected individuals at high risk of progression to active 
TB disease. These individuals should receive anti-TB che-
moprophylaxis after thorough testing to eliminate active TB 
disease. IGRAs based on specific RD1 peptides have shown 
promising results for diagnosing LTBI not only in immuno-
competent individuals, but also in HIV-infected persons at 
higher risk for development of active disease. Although, 
these dichotomous (positive/negative) measures cannot dis-
tinguish between LTBI and active disease, operational re-
search clinical studies are ongoing to demonstrate their po-
tential role in predicting the risk of progression. Evidence 
coming from studies showing a high ratio of combined quan-
titative T-SPOT-TB results to CD4+ cell count in patients 
with active TB should be confirmed in different settings in 
order to classify patients with active TB from those with 
LTBI. It is thus likely that tuberculin skin testing being 
largely inadequate in these immunocompromised patients 
will be in the next future substituted for the IGRAs. 
  Other issues need to be resolved in relation to the identi-
fication of correlates of immune protection or “functional 
biomarkers” that will facilitate the rational design for drugs 
 
* -LTBI = anti-LTBI treatment. 
Fig. (3). New possible algorithm for targeting HIV-infected individual establishing the highest risk group and the specific treatment chemo-
prophylaxis. IGRA (Interferon-gamma release assay), WBKA (Whole Blood Killing Assay), ELISA (antibody assay with PGL-Tb1). 
HIV (+)
IGRA 
IGRA (-)  IGRA (-) 
ELISA  Serial IGRA 
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(-)  (+)  (+)  (-) 
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< 50-100 CD4+/µL  > 50-100 CD4+/µL
WBKA 
(+)  (-) 
HAART  α-LTBI* α-LTBI* No treatment WBKA  Follow up58    The Open Respiratory Medicine Journal, 2008, Volume 2  Lagrange and Herrmann 
for the clearance of TB infection. After validation, the 
WBKA will find its right place among a new algorithm that 
might facilitate the management of HIV-infected individuals 
at high risk of progression. Similarly, antibody markers 
might predict ongoing progression from latent to active TB 
in HIV-positive subjects, including those with negative PPD 
skin test or with indeterminate IGRA results. 
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